98%
921
2 minutes
20
Aims: Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end-stage liver disease (MELD) score and its variations in predicting adverse outcomes [death, urgent heart transplant, and left ventricular assist device (LVAD) implant] among patients with AHF to assess the clinical associations of the MELD score in this population and to compare the efficacy of this tool with other prognostic scores in AHF.
Methods And Results: In this longitudinal prospective study, 162 patients with advanced heart failure (AHF) were enrolled; all patients included in the study were receiving the maximum tolerated medical therapy according to guidelines. The MELD score was measured at baseline and every 6 months during follow-up. All patients underwent echocardiographic assessment and cardiopulmonary testing, which included the evaluation of maximal oxygen uptake (VO2max) and the minute ventilation/carbon dioxide production (VE/VCO2) slope. The mean age of the study group was 57.7 ± 11.6 years. There were 26 deaths, 5 urgent transplants, and 1 LVAD implantation during a follow-up period of 31.4 ± 15.6 months. The mean New York Heart Association (NYHA) class was 2.8 ± 0.5, ejection fraction (EF) was 26.3 ± 6.5%, the mean VO2max was 11.7 ± 3.5 mL/kg/min. Multiple regression analysis revealed a positive correlation between the MELD score and NT-proBNP (β = 0.215; P = 0.041) and furosemide dosage (β = 0.187; P = 0.040). Conversely, a negative correlation was observed between the MELD score and TAPSE (β = -0.204; P = 0.047). Multivariate Cox regression on combined outcome shows a HR of 1.094 (95% CI 1.003-1.196) for unit increase in MELD considered as a continuous variable. The predictive role is independent by the effect of covariates considered in the analysis such as age, sex, NYHA class, EF, TAPSE, PASP, VO2max, NT-proBNP, MELD score worsening, and NT-proBNP increase. Changes in MELD score percentage, considered as a dichotomous variable (≤100% and >100%), were found to be predictors of mortality, urgent heart transplant and LVAD implant. Receiver operating characteristic (ROC) curves showed an area under the curve (AUC) of 0.887 for MELD score and composite outcome of death, urgent transplant, and need for LVAD. The predictive performance of MELD was even superior compared with MELD-Na, MELD-XI, MAGGIC risk score, and MECKI.
Conclusions: The MELD score and its longitudinal changes are effective predictors of adverse outcomes in AHF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911564 | PMC |
http://dx.doi.org/10.1002/ehf2.15002 | DOI Listing |
Hepatology
September 2025
Department of Gastroenterology and Hepatology, UT Southwestern, Dallas, TX.
Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.
View Article and Find Full Text PDFLiver Int
October 2025
Hannover Medical School, Department of Diagnostic and Interventional Radiology, Hannover, Germany.
Background And Aims: We aimed to ascertain the prevalence of sarcopenia in patients with primary sclerosing cholangitis (PSC) and to assess the prognostic value as a biomarker for disease outcome.
Methods: We collected data from 224 patients (148 male, 76 female; mean age 41 years) from January 2002 to December 2021, with a confirmed diagnosis of PSC who underwent magnetic resonance imaging (MRI). Muscle mass was quantified at the level of the third lumbar vertebra by measurement of psoas muscle thickness (PMT) and total psoas muscle area (PMA).
PLoS One
September 2025
School of Software, Hunan College of Information, Chang sha, Hunan Province, China.
This research has proposed a new Emotion Recognition in Conversation (ERC) model known as Hierarchical Graph Learning for Emotion Recognition (HGLER), built to go beyond the existing approaches that find it difficult to request long-distance context and interaction across different data types. Rather than simply mixing different kinds of information, as is the case with traditional methods, HGLER uses a 2-part graph technique whereby conversations are represented in a 2-fold manner: one aimed at illustrating how various parts of the conversation relate and another for enhancing learning from various types of data. This dual-graph system can represent multimodal data value for value by exploiting the benefits of each type of data yet tracking their interactions.
View Article and Find Full Text PDFHepatol Commun
September 2025
Department of Internal Medicine, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Background: Steatotic liver diseases (SLDs) and their subcategories-metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD)-significantly contribute to liver-related and extrahepatic morbidity and mortality. This project aimed to assess the landscape of SLDs and clinically significant fibrosis (CSF) before (2017-2020) and during (2021-2023) the COVID-19 pandemic.
Methods: Using National Health and Nutrition Examination Survey (NHANES) data, we analyzed 8965 prepandemic and 6337 pandemic participants aged ≥18 years.
Infect Dis Ther
September 2025
The Third Clinical Medical College, Qingdao University School of Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.
View Article and Find Full Text PDF